Rxcurve
HCPCS J9185 · per 50 MG

Fludarabine phosphate inj

Products billed under this code include Fludarabine Phosphate.

Payment limit per 50 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under J9185

From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.

ProductLabelerNDCUnits / pkgLimit / pkg
Fludarabine Phosphate Hikma Pharmaceuticals USA Inc. 24201-0237-01 1 $177.924
Fludarabine Phosphate Sagent Pharmaceuticals 25021-0242-02 1 $177.924
Fludarabine Phosphate Actavis Pharma, Inc. 45963-0609-55 1 $177.924
Fludarabine Phosphate Areva Pharmaceuticals 59923-0604-02 1 $177.924
Fludarabine Phosphate FreseniUS Kabi USA, LLC 63323-0192-02 1 $177.924

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
4Q26 $177.924 −$28.375 50 MG Fludarabine phosphate inj v1, posted September 17, 2026
3Q26 $206.299 −$11.427 50 MG Fludarabine phosphate inj v1, posted September 15, 2026
2Q26 $217.726 +$136.317 50 MG Fludarabine phosphate inj v1, posted September 15, 2026
1Q26 $81.409 +$13.212 50 MG Fludarabine phosphate inj v1, posted September 15, 2026
4Q25 $68.197 −$3.452 50 MG Fludarabine phosphate inj v1, posted September 8, 2026
3Q25 $71.649 +$12.12 50 MG Fludarabine phosphate inj v1, posted March 10, 2026
2Q25 $59.529 −$108.771 50 MG Fludarabine phosphate inj v1, posted March 10, 2026
1Q25 $168.30 +$34.146 50 MG Fludarabine phosphate inj v1, posted December 19, 2025
4Q24 $134.154 −$95.15 50 MG Fludarabine phosphate inj v1, posted June 11, 2025
3Q24 $229.304 +$38.409 50 MG Fludarabine phosphate inj v1, posted June 11, 2025
2Q24 $190.895 +$16.926 50 MG Fludarabine phosphate inj v1, posted March 11, 2025
1Q24 $173.969 −$326.49 50 MG Fludarabine phosphate inj v1, posted December 19, 2024
4Q23 $500.459 −$104.289 50 MG Fludarabine phosphate inj v1, posted October 10, 2024
3Q23 $604.748 +$443.002 50 MG Fludarabine phosphate inj v1, posted June 5, 2024
2Q23 $161.746 +$56.146 50 MG Fludarabine phosphate inj v1, posted February 23, 2024
1Q23 $105.60 +$13.386 50 MG Fludarabine phosphate inj v1, posted December 6, 2023
4Q22 $92.214 +$44.152 50 MG Fludarabine phosphate inj v1, posted June 22, 2023
3Q22 $48.062 −$12.125 50 MG Fludarabine phosphate inj v1, posted June 9, 2023
2Q22 $60.187 +$3.167 50 MG Fludarabine phosphate inj v1, posted December 14, 2022
1Q22 $57.02 −$12.321 50 MG Fludarabine phosphate inj v1, posted June 8, 2022
4Q21 $69.341 −$25.159 50 MG Fludarabine phosphate inj v1, posted June 2, 2022
3Q21 $94.50 +$19.324 50 MG Fludarabine phosphate inj v1, posted June 2, 2022
2Q21 $75.176 +$20.20 50 MG Fludarabine phosphate inj v1, posted March 1, 2022
1Q21 $54.976 – 50 MG Fludarabine phosphate inj v1, posted December 10, 2021

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files